Imeik Technology Development Co Ltd
SZSE:300896
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
134.05
282.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Imeik Technology Development Co Ltd
Imeik Technology Development Co Ltd
Cash & Cash Equivalents
Imeik Technology Development Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash & Cash Equivalents
¥2.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
¥15B
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash & Cash Equivalents
¥2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash & Cash Equivalents
¥3.8B
|
CAGR 3-Years
75%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
20%
|
|
Imeik Technology Development Co Ltd
Glance View
Imeik Technology Development Co Ltd. is a pioneering player in the fast-growing field of biotechnology, primarily focusing on advanced skin care solutions. Founded in 2010, the company has rapidly positioned itself at the forefront of the beauty and personal care sectors in China. Leveraging cutting-edge research and development, Imeik specializes in hyaluronic acid products, which are widely recognized for their hydrating properties and overall skin improvement. The firm’s commitment to innovation and quality has not only allowed it to capture significant market share, but also to attract strategic partnerships with global brands. With a robust production capacity and a keen eye on market trends, Imeik aims to meet the increasing consumer demand for effective and scientifically-backed skincare solutions. In recent years, Imeik has witnessed impressive financial growth, driven by the expanding awareness of skincare among Chinese consumers and a surge in online retail. The company’s successful IPO on the Shenzhen Stock Exchange has positioned it for further expansion and development, putting capital towards research initiatives and marketing strategies that bolster brand recognition. As sustainability becomes more important to consumers, Imeik's focus on eco-friendly practices enhances its appeal, promising not only to captivate beauty enthusiasts but also to draw in investors looking for companies with a commitment to responsible practices. With their sights firmly set on international markets, Imeik Technology Development Co Ltd is poised for sustained growth, presenting an intriguing opportunity for investors eager to tap into the lucrative beauty and biotechnology sectors.
See Also
What is Imeik Technology Development Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.4B
CNY
Based on the financial report for Dec 31, 2023, Imeik Technology Development Co Ltd's Cash & Cash Equivalents amounts to 2.4B CNY.
What is Imeik Technology Development Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
56%
Over the last year, the Cash & Cash Equivalents growth was -22%. The average annual Cash & Cash Equivalents growth rates for Imeik Technology Development Co Ltd have been -11% over the past three years , 56% over the past five years .
You don't have any saved screeners yet
